Stocktoria
Voyager Therapeutics, Inc. VYGR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-11-11
Voyager Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -326.6% | -104.1% | 48.8% | -124.3% | -196.8% |
| Net margin | -296.5% | -81.3% | 52.9% | -113.4% | -190.3% |
| FCF margin | -334.5% | -23.5% | 29.9% | -36.7% | -147.4% |
| Return on assets | -47.5% | -16.5% | 37.7% | -29.1% | -36.7% |
| Return on equity | -61.1% | -21.7% | 56.0% | -78.6% | -74.9% |
| Current ratio | 7.64 | 5.56 | 4.96 | 1.72 | 2.68 |
| Revenue growth | -49.5% | -68.0% | 511.2% | 9.3% | -78.1% |
Source: SEC EDGAR filings · CIK 0001640266 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.